Caerin 1.9 is a natural peptide derived from the skin secretions of the Australian tree frog (Litoria) with broad-spectrum antimicrobial and anticancer bioactivity. It improves the efficacy of a therapeutic vaccine and immune checkpoint inhibitor therapy when injected intratumorally and inhibits TC-1 tumor growth when applied topically through intact skin in a TC-1 murine tumor model. This paper investigated the pharmaceutical kinetic profile, the tissue distribution, and the acute safety investigation of Caerin 1.9 peptide in Sprague Dawley (SD) rats. The results showed that subcutaneous injection of Caerin 1.9 at 100mg/kg is safe and does not cause mortality or organ malfunction in the recipient rats. For the consecutive injection of F3 at 10mg/kg, the peak concentration (Cmax) of F3 displayed at 1hr after injection in male rats was 591ng/mL, the average drug retention time was 0.807hr, T1/2 was 4.58hr, and AUC0-last was 1890h×ng/mL. In female rats, Cmax was 256ng/mL, with an average drug retention time of 2.96hr, T1/2 of 1.33hr, and AUC0-last of 740h×ng/mL. The results showed that the concentration of Caerin 1.9 in the peripheral blood peaked at 1 hour. As injected concentration increased, T1/2 extended, and Cmax, AUC0-last, and volume of distribution at a steady state all increased. After 14 days of repeated subcutaneous injection at 10.0mg/kg, no accumulation of Caerin 1.9 in plasma was observed. The results of tissue distribution showed that the Caerin 1.9 is below the LC-MS/MS detection threshold at a minimum concentration of 40ng/g. In conclusion, Caerin 1.9 is well tolerated in rats and could be used with current immunotherapies for better management of solid tumors and genital warts.
Objectives: With rising rates of maxillofacial fracture, postoperative infection following rigid internal fixation is an important issue that requires immediate resolution. It is important to explore an alternative antibacterial method apart from conventional antibiotics. A controlled experiment was conducted to evaluate the effectiveness of a caerin 1.9 peptide -coated titanium plate in reducing mandibular infection in New Zealand (NZ) rabbits, aiming to minimise the risk of post-metallic implantation infection. Methods: Twenty-two NZ rabbits were randomly divided into 3 groups. The experiment group received caerin 1.9 peptide-coated titanium plates and mixed oral bacteria exposure. The control group received normal titanium plates with mixed oral bacteria exposure. The untreated group served as a control to prove that bacteria in the mouth can cause infection. Weight, temperature, hepatic function, and C-reactive protein levels were measured. Wound and bone conditions were evaluated. Further analysis included local infection, anatomic conditions, histology, and bacterial load. Results: No significant differences were found in temperature, weight, blood alanine aminotransferase, and C-reactive protein levels amongst the 3 groups. The experiment group showed the lowest amount of bacterial RNA in wounds. Additionally, the experiment group had higher peripheral lymphocyte counts compared to the control group and lower neutrophil counts on the third and seventh day postoperatively. Histologic analysis revealed lower levels of inflammatory cell infiltration, bleeding, and areas of necrosis in the experimental group compared with the controls. Conclusions: A caerin 1.9-coated titanium plate is able to inhibit bacterial growth in a NZ rabbit mandibular mixed bacteria infection model and is worth further investigation. (c) 2024 Published by Elsevier Inc. on behalf of FDI World Dental Federation. This is an open (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Implant-associated infections and foreign body responses remain major challenges in orthopedic and biomedical implant applications. In this study, we report a novel strategy to enhance the antibacterial and biocompatibility properties of magnesium (Mg) alloy implants by applying a biodegradable polycaprolactone (PCL) coating embedded with the host-defense peptide, caerin 1.9 (F3). Three Mg-based specimens, including pure Mg, cold-extruded AZ31, and fully annealed AZ31 (3A), were evaluated following PCL-F3 surface modification. The PCL-F3 coatings demonstrated sustained antibacterial efficacy both in vitro and in vivo, effectively inhibiting methicillin-resistant Staphylococcus aureus (MRSA) for up to 168 h. Among the groups, the 3A-PCL-F3 condition exhibited the most notable performance, with substantially enhanced corrosion resistance, reduced inflammatory responses, and no detectable toxicity to vital organs. In vivo proteomic and metabolomic analyses further revealed that the 3A-PCL-F3 implants promoted the expression of osteogenic markers and activated pathways related to bone mineralization and hemostasis, while avoiding prolonged inflammatory activation at 3 months post-implantation. Notably, histological and cytokine ELISA data confirmed favorable tissue responses, including suppressed IL-1β and IL-10 levels and signs of early immune activation that subsided over time. These findings indicate that PCL-F3-coated Mg alloys, particularly the 3A variant, represent a promising solution for biodegradable implants with dual antibacterial and regenerative functionality. This work lays the foundation for developing degradable Mg alloy biomaterials with enhanced biocompatibility and multifunction for clinical use.
2 September 2025 in Materials Science and Engineering: A